Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
St George's, University of London
Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural history of Fabry disease has proven poor survival to ages \>50 years outlining the importance to evaluate cardiac symptoms and outcomes of patients with Fabry disease.
This study is a prospective cohort study and observes patients since 2001. Through this long-term experience and the relative high number of patients this study is suggested to help estimating the risk of cardiac arrhythmias and sudden cardiac death (SCD) as well as death or heart transplantation due to terminal heart failure.
All patients in treatment in the Fabry Center Wuerzburg (FAZiT) are included in this study if informed consent is provided.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fabry disease (genetically confirmed)
Signed informed consent
18 years and older
You may not be if
No informed consent
Withdrawal of informed consent
Clareo Health | Evaluation of HEArt invoLvement in Patients With FABRY Disease